- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.11. | Voyager, Transition Bio set sail on neuro research trek in search for small molecule candidates | ||
| 10.11. | AI-driven Iambic raises $100M-plus as it looks to advance pipeline, strike more deals | ||
| 10.11. | Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle | ||
| 10.11. | Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts | ||
| 10.11. | AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail | ||
| 10.11. | Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T | ||
| 10.11. | Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed | ||
| 10.11. | AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win | ||
| 10.11. | FDA puts Tenaya heart disease gene therapy clinical trial on hold | ||
| 10.11. | Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds | ||
| 08.11. | Pfizer beats out Novo with $10B agreement to buy Metsera | ||
| 07.11. | Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates | ||
| 07.11. | Patient dies after receiving Intellia's CRISPR therapy | ||
| 06.11. | FDA reveals second round of 'national priority' voucher winners, including obesity giants Lilly and Novo | ||
| 06.11. | Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D | ||
| 06.11. | Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition | ||
| 06.11. | UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data | ||
| 06.11. | Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3 | ||
| 06.11. | Moderna's phase 3 norovirus study heads north again after struggling to find cases down south | ||
| 06.11. | Inflammation biotech Evommune heads to NYSE with $150M IPO | ||
| 06.11. | AstraZeneca drops MASH drug over disappointing phase 2 data | ||
| 06.11. | Dynavax pays Vaxart $30M for oral COVID-19 vaccine program | ||
| 05.11. | FTC warns Novo that current Metsera offer structure may violate US merger law | ||
| 05.11. | Novo drops oncology ambitions, early-stage MASH prospects in ongoing R&D shake-up | ||
| 05.11. | Lilly pulls out of CNS portion of $960M RIPK1 inhibitor collab with Rigel |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .